BioSpace News Archive

Sirona Biochem Corp. announces the voting results from its Annual General Meeting of Shareholders, held in Vancouver, British Columbia on December 30, 2022.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on December 30, 2022.

Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, provided a business update for its operations and clinical trial development programs.

OncoC4, Inc. announced that the first patient has been dosed in the Phase 2 combination study of ONC-392, a nextgen target-preserving anti-CTLA-4 antibody and KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with platinum-resistant ovarian cancer .

Vistagen announced that the Company has taken important strategic steps to secure additional patent protection for its lead product candidate, PH94B, through the recent filing of national applications at the U.S. Patent and Trademark Office and counterpart patent authorities in major pharmaceutical markets outside the U.S. for the treatment of adjustment disorder.

BeiGene, a global biotechnology company announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental biologics license application for tislelizumab in patients with first-line unresectable or metastatic hepatocellular carcinoma.

ValnevaSE, a specialty vaccine company, reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced that, effective December 27, 2022, its independent directors approved an equity award under Helius’ 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company.

MedMira Inc., reported on its financial results for the quarter ended October 31, 2022.